Concurrent treatment with tamoxifen and CYP2D6 inibitors: clinical significance of drug interactions

被引：0

作者：

Seruga, Bostjan ^{[1
]}

Sarotar, Brigita Novak ^{[2
]}

Knez, Lea ^{[3
]}

Borstnar, Simona ^{[1
]}

Jansa, Rado ^{[4
]}

Kocmur, Marga ^{[5
]}

Cufer, Tanja ^{[3
]}

机构：

[1] Onkol Inst Ljubljana, Sektor Internistitne Onkol, Ljubljana, Slovenia

[2] Psihiatricna Klin Ljubljana, Ljubljana 1260, Slovenia

[3] Bolnisnica Golnik, Golnik 4204, Slovenia

[4] Univ Klin Ctr Ljubljana, Klin Oddelek Gastroenterol, Ljubljana 1000, Slovenia

[5] Psihiatrija Kocmur Marga Doo, Ljubljana 1000, Slovenia

来源：

ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL | 2012年 / 81卷 / 7-8期

关键词：

tamoxifen; CYP2D6; antidepressants; BREAST-CANCER-TREATMENT; DEPRESSION; WOMEN; METABOLISM; INHIBITORS; GENOTYPE; COHORT;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Tamoxifen is used in the treatment of women with endocrine responsive breast cancer. It is a prodrug, which is metabolized by liver cytochrome P450 system (GYP) into metabolites with a potent anti-estrogenic activity; CYP2D6 is one of the most important enzymes involved in this metabolic pathway. Low or absent activity of CYP2D6, which can be inherited and/or can occur due to the use of CYP2D6 inhibitors, may impair outcome in women with tamoxifen-treated breast cancer. Antidepressants, which can also inhibit CYP2D6, are among the most commonly prescribed drugs in women with breast cancer. Breast cancer patients receiving tamoxifen should not be co-prescribed antidepressants or any other drugs, which are potent inhibitors of CYP2D6.

引用

页码：526 / 532

页数：7

共 24 条

[1]

[Anonymous], EUR NEUROPSYCHOPHARM

[2]

Aubert RE, 2009, J CLIN ONCOL, V27, p18S

[3] Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment [J].

Borges, Silvana ;

Desta, Zeruesenay ;

Li, Lang ;

Skaar, Todd C. ;

Ward, Bryan A. ;

Nguyen, Anne ;

Jin, Yan ;

Storniolo, Anna Maria ;

Nikoloff, D. Michele ;

Wu, Lin ;

Hillman, Grant ;

Hayes, Daniel F. ;

Stearns, Vered ;

Flockhart, David A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) :61-74

[4] Depression and anxiety in women with early breast cancer: five year observational cohort study [J].

Burgess, C ;

Cornelius, V ;

Love, S ;

Graham, J ;

Richards, M ;

Ramirez, A .

BRITISH MEDICAL JOURNAL, 2005, 330 (7493) :702-705

[5]

Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI [10.1200/JCO.2009.26.3756, 10.1200/JOP.000082]

[6] Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis [J].

Cipriani, Andrea ;

Furukawa, Toshiaki A. ;

Salanti, Georgia ;

Geddes, John R. ;

Higgins, Julian P. T. ;

Churchill, Rachel ;

Watanabe, Norio ;

Nakagawa, Atsuo ;

Omori, Ichiro M. ;

McGuire, Hugh ;

Tansella, Michele ;

Barbui, Corrado .

LANCET, 2009, 373 (9665) :746-758

[7] Interactions Between Tamoxifen and Antidepressants via Cytochrome P450 2D6 [J].

Desmarais, Julie Eve ;

Looper, Karl J. .

JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (12) :1688-1697

[8] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6 [J].

Desta, Z ;

Ward, BA ;

Soukhova, NV ;

Flockhart, DA .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (03) :1062-1075

[9] Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer [J].

Dezentje, Vincent O. ;

van Blijderveen, Nico J. C. ;

Gelderblom, Hans ;

Putter, Hein ;

van Herk-Sukel, Myrthe P. P. ;

Casparie, Mariel K. ;

Egberts, Antoine C. G. ;

Nortier, Johan W. R. ;

Guchelaar, Henk-Jan .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) :2423-2429

[10]

Dolzan V, 2002, ZDR VESTN, V71, P457

← 1 2 3 →